IGF1R and colorectal cancer: For therapeutic intervention, colorectal cancer organoid and in vivo studies demonstrated the benefit of co-targeting IGF1R and YAP1 with the anti-IGF1R tyrosine kinase inhibitor (TKI) picropodophyllin (PPP) and verteporfin (VP), a YAP1 inhibitor [72].